Genetic testing for childhood immune defects: prep checklist

The diagnostic landscape has changed substantially: the International Union of Immunological Societies (IUIS) now classifies 485 or more distinct genetic defects across 10 categories, and roughly 1 in 2,000 people in the United States carry some form of primary immunodeficiency. These conditions are still individually uncommon, but they are no longer a rare-disease curiosity that can be approached with an improvised workup.

The practical problem begins once a clinician or family decides that genetic testing is warranted. A useful result depends on what happens before the sample reaches the laboratory: how the family history is reconstructed, whether the clinical phenotype is documented clearly, which test is selected, and whether the specimen is appropriate for the child’s treatment history. Vaccine safety, insurance authorization, and transplant-related sampling can all change the diagnostic pathway.

This pediatric genetic testing checklist for immune disorders is built around that operational reality. It follows the preparation steps that matter in practice, from mapping three generations of family health histories to choosing between a targeted panel and broader sequencing, managing live-attenuated vaccines, planning for financial barriers, and obtaining constitutional DNA after transplantation.

Mapping Three-Generation Family Health Histories

Family history is the lowest-cost, highest-yield preparatory step in the entire workflow, and it is also the step most often completed superficially. A useful pedigree covers three generations: the child, parents, siblings, aunts, uncles, cousins, and both sets of grandparents. It should include relatives on both sides of the family, even when the suspected disorder appears to follow a familiar inheritance pattern.

The clinical questions are not abstract. They target patterns that can move an IEI up or down the differential and help the laboratory interpret a variant later.

I look for specific patterns rather than vague recollections:

• Recurrent or unusual infections that required intravenous antibiotics, hospitalization, prolonged treatment, or repeated procedures. In male maternal relatives, this pattern may raise suspicion of an X-linked condition.
• Infections caused by organisms that would be unusual in otherwise healthy children, or infections that were unusually severe, persistent, or difficult to clear.
• Autoimmune cytopenias, inflammatory bowel disease without a clear explanation, vasculitis, severe eczema, or other inflammatory disease appearing at an unusually young age.
• Early unexplained deaths, particularly during infancy or before age five, that were attributed to infection, sudden infant death, complications of prematurity, or another nonspecific cause without a complete diagnostic explanation.
• Consanguinity in the parental line, which can increase the likelihood of autosomal recessive conditions.
• Immune globulin replacement therapy, bone marrow or hematopoietic stem cell transplantation, documented hypogammaglobulinemia, or a known diagnosis of primary immunodeficiency in any family member.
• Multiple children in the same family with infections, developmental concerns, unexplained inflammation, or early death, even if the clinical presentations were not identical.
• Miscarriages or stillbirths when the family history suggests a severe inherited disorder, while recognizing that this information is often incomplete and should be handled carefully.

The age at which a relative became ill matters as much as the label attached to the illness. A series of hospitalizations in infancy has a different diagnostic weight from occasional respiratory infections in adulthood. The same is true of treatment intensity. A relative described as having “pneumonia” may have had one uncomplicated episode, or may have experienced repeated admissions, respiratory failure, and unusual organisms. Those are not equivalent data points.

Documenting this takes time. Families often arrive with a strong sense that a disorder runs in the family but no usable paper trail. Before the genetic counseling visit, I ask them to contact relatives and record who was affected, at what age, with what symptoms, what treatment was required, and what the eventual outcome was. Medical records are useful when they can be obtained, but a carefully dated family account is still better than a general statement that several relatives were sick.

The pedigree serves two purposes. First, it helps the clinical team decide whether a targeted childhood immunodeficiency genetic panel is likely to be informative or whether broader sequencing is more appropriate. Second, it helps with variant interpretation. A variant of uncertain significance (VUS) may be more or less persuasive depending on whether it tracks with disease across affected relatives, appears in unaffected relatives, or is absent from the family members who can be tested.

A clean family history does not rule out an IEI. De novo variants can arise in a child without a previous family pattern, and autosomal recessive conditions can appear in a child whose parents are both unaffected carriers. Severe combined immunodeficiency (SCID), in particular, may present without an obvious family history. The pedigree is a guide to inheritance and interpretation, not an exclusion test.

It is also worth separating family history from family assumptions. Parents may describe a relative as having an “immune problem” when the original diagnosis was never confirmed. That description should not be discarded, but it should not be treated as established genetic evidence either. The most useful record distinguishes documented diagnoses from remembered symptoms and from family terminology.

Selecting the Right Diagnostic Modality: Panels vs. Sequencing

The choice between a targeted primary immunodeficiency panel and broad sequencing is not binary. It is a stratified decision based on the clinical phenotype, the results of functional immune testing, the suspected inheritance pattern, the urgency of the case, and the consequences of missing a diagnosis.

What a targeted panel can do well

Targeted PID panels interrogate a curated set of genes known to cause IEIs. The exact size depends on the laboratory and the test design, but the panel may include several hundred genes. Because the analysis is focused, the laboratory can concentrate coverage and interpretation on genes with an established relationship to immune disease.

A panel is often a sensible first test when the phenotype already points toward immunodeficiency. Examples include a child with confirmed hypogammaglobulinemia, a characteristic SCID newborn-screen result, persistent abnormalities in lymphocyte subsets, or a family history that strongly suggests a known syndrome. A clear phenotype does not guarantee a positive result, but it makes a focused test easier to interpret and more likely to answer the immediate clinical question.

Targeted testing generally has a shorter turnaround, often around three to six weeks. Out-of-pocket costs average around $1,500 when insurance does not cover the test. The focused design can also produce fewer variants of uncertain significance than broad sequencing, although the number and clinical relevance of reported variants still depend on the laboratory.

A panel is not simply a cheaper version of WES or WGS. It is a different diagnostic instrument. Its strengths are focus, speed, and interpretive manageability. Its limitations are equally important: it may not include a newly described gene, may not resolve every structural or copy-number change, and may not explain a phenotype that does not fit the panel’s existing gene list.

When broader sequencing is the better first move

Whole-exome sequencing (WES) examines protein-coding regions, while whole-genome sequencing (WGS) surveys the genome more broadly. These approaches can capture atypical presentations, syndromic features, and candidate genes that are not included on a standard IEI panel. WGS may also provide broader detection of some structural and noncoding changes, although performance still depends on the laboratory, the analysis pipeline, and the type of variant involved.

WES or WGS is often appropriate when the phenotype is ambiguous, when several organ systems are involved, or when a targeted panel has returned negative despite a high level of clinical suspicion. It is also useful when the child has developmental, skeletal, dermatologic, neurologic, or gastrointestinal findings that suggest a broader genetic syndrome rather than an isolated immune defect.

Turnaround for WES is often longer, commonly around eight to sixteen weeks. Out-of-pocket costs may range from $4,000 to $12,000, depending on the laboratory, insurance status, and whether trio testing is ordered. Those figures should be discussed as an absolute range rather than reduced to a single ratio. The difference between a $1,500 panel and sequencing priced at $4,000 is not the same as the difference between that panel and sequencing priced at $12,000.

Trio testing includes the affected child and both biological parents. It can substantially improve interpretation by showing whether a variant is de novo, inherited from one parent, present in both parents, or absent from the expected relatives. That information can make an apparently ambiguous finding more interpretable, although trio testing does not eliminate uncertainty.

The clinical phenotype should drive the decision, not the perceived prestige of the broader test. A larger test is not automatically a better test if the clinical question is poorly defined. Conversely, a narrow panel can be a false economy when the presentation is clearly multisystem or when previous testing has already made a focused approach less useful.

Genetic results still need functional context

Genetic sequencing cannot replace functional immunological assays. Depending on the suspected defect, the evaluation may include flow cytometry for T-cell, B-cell, and NK-cell subsets; quantitative immunoglobulins; vaccine-specific antibody titers; lymphocyte proliferation studies; complement testing; or oxidative burst testing when chronic granulomatous disease is a concern.

These tests answer different questions. Sequencing may identify a potentially pathogenic change, while functional testing can show whether a relevant immune pathway is actually impaired. In some conditions, a genetic result clarifies a borderline functional finding. In others, a normal functional study can change how seriously a variant should be considered.

The most common error in this part of the workup is treating a negative genetic test as an exclusion. Sequencing can miss deep intronic variants, some structural variants, variants outside the regions adequately covered by the assay, and genes that have not yet been linked to disease. A negative panel in a clinically suspicious case is a reason to review the phenotype and consider expanded testing, reanalysis, or additional functional studies. It is not, by itself, a reason to dismiss the diagnosis.

The reverse problem also occurs: a positive result can be overinterpreted. A pathogenic variant must be considered in the context of the child’s symptoms, immune phenotype, inheritance pattern, and the known disease mechanism. A laboratory report is an important piece of the diagnosis, but it is not a substitute for clinical correlation.

Critical Safety Protocols: Managing Live-Attenuated Vaccines

This is where preparation becomes a clinical safety issue. Children with suspected severe T-cell or combined immunodeficiency can be harmed by live-attenuated vaccines before the immune defect has been evaluated and the child has been cleared by an immunologist.

The relevant live-attenuated vaccines include measles, mumps, and rubella (MMR), rotavirus, varicella, and the nasal-spray influenza formulation. Inactivated or non-live vaccines, including DTaP, IPV, hepatitis B, injected influenza, and pneumococcal conjugate vaccines, are managed differently and should not be delayed without a clinical reason. Vaccine decisions must still be individualized to the child’s immune status and current treatment plan.

The operational rule is straightforward: when severe T-cell or combined immunodeficiency is suspected, live-attenuated vaccines should be held until an immunologist formally clears the child. This rule applies whether or not genetic testing has been ordered and whether or not the results are expected soon. A pending test is not a safety assessment.

Communication is part of the protocol. If a pediatrician identifies a concerning newborn-screen result or a pattern suggestive of SCID, the vaccine hold needs to be documented and communicated to the family, the immunology team, and any other clinicians who may administer vaccines. Families should know which vaccines are affected and should be advised to mention the suspected immune defect before a visit with another healthcare professional.

If the child has already received a rotavirus vaccine before SCID was suspected, that information must reach the clinical team promptly. Vaccine-strain rotavirus can be shed for an extended period in immunocompetent hosts and can cause prolonged or severe disease in children with SCID. The relevant response is not to assign blame; it is to make sure the exposure is recognized and incorporated into management.

Household vaccination can also require discussion. The child’s clinicians should provide specific guidance about the vaccines received by close contacts, because the risk depends on the vaccine, the child’s immune defect, and the clinical circumstances. Families should not be left to infer these rules from a general internet search.

A negative genetic panel does not clear a child for live-attenuated vaccines when severe immunodeficiency is still suspected. Vaccine clearance comes from the immunologist, not from a laboratory report.

The same principle applies to other urgent precautions. A child with a possible severe immune defect may need rapid review of infection exposures, blood-product requirements, and prophylactic treatment while the diagnostic workup is still in progress. Genetic testing is important, but it does not replace immediate clinical risk management.

Navigating Financial Realities and Insurance Coverage

Cost discussions should use absolute figures and the actual billing pathway, not a simplified comparison that implies a fixed price difference. In the ranges used for these tests, a targeted panel is about $1,500 on average when insurance does not cover it, while WES or WGS may cost approximately $4,000 to $12,000 out of pocket. That means the financial difference can be substantial, but it varies widely depending on where the sequencing test falls within that range.

Insurance coverage is similarly variable. Prior authorization is common, particularly for sequencing. Authorization establishes that the insurer considers the test medically necessary under the plan’s rules; it does not necessarily determine how much the family will pay. A high-deductible plan may leave the family responsible for a significant portion of the allowed cost even after approval.

A few operational points matter:

• Commercial laboratories often require a clinical justification letter from the ordering physician. The letter may come from a clinical immunologist, geneticist, or, in some cases, a pediatrician documenting specialist consultation and the medical rationale for testing.
• The request should describe the phenotype rather than rely on a broad label such as recurrent infections. Relevant details include infection severity, age at onset, organisms, hospitalizations, immune-function results, growth concerns, autoimmunity, family history, and previous genetic testing.
• Trio testing adds cost, but it can substantially improve variant interpretation by clarifying inheritance. The decision should be discussed before the sample is collected, since adding parental samples later may delay analysis or require a new authorization.
• Families should ask whether the quoted amount includes analysis, parental testing, reanalysis, genetic counseling, and the reporting of secondary findings. The answer varies by laboratory and by the test ordered.
• Institutional assistance programs, payment plans, and no-cost testing may be available for selected indications. These programs are not always prominent on a laboratory website, so the ordering clinic or laboratory billing office may need to be contacted directly.
• The final responsibility depends on the insurer, the laboratory network, the plan’s deductible and coinsurance rules, and whether the test is classified as diagnostic rather than screening.

For families paying out of pocket, a targeted panel may be a rational first step when the clinical phenotype is clear and the relevant genes are well represented on the panel. The stated average panel cost is about $1,500, while the stated WES/WGS range is $4,000–$12,000. Those are the figures families should use when planning, rather than being told that one test is always a fixed fraction of the other.

The financial decision should not be separated from clinical urgency. If the child has a severe phenotype, a concerning newborn-screen result, or an immediate treatment decision, delaying broader testing solely to start with a less expensive test may not be appropriate. Conversely, ordering WES or WGS without a defined clinical question can create more uncertainty without necessarily improving care. The right test is the one that addresses the current diagnostic problem while leaving a sensible next step if the result is negative or inconclusive.

Special Considerations for Post-Transplant Genetic Sampling

This is the constraint that can catch transplant teams off guard. In a child who has undergone bone marrow or hematopoietic stem cell transplantation, a standard blood sample may not represent the child’s constitutional genome. The circulating blood cells can be donor-derived rather than derived from the child’s original hematopoietic system.

Saliva is not automatically a solution. Although saliva contains epithelial material that may be patient-derived, it can also be contaminated with donor leukocytes, particularly in immunocompromised patients. The degree of contamination can make the result difficult to interpret or unsuitable for the specific variant being investigated.

The clinically usable options include:

1. Pre-transplant banked samples. DNA, fibroblasts, or another appropriately collected sample obtained before transplantation is usually the cleanest option. This is why transplant teams should bank constitutional material whenever feasible, especially when an IEI is suspected but not yet genetically confirmed.

2. Cultured skin fibroblasts from a punch biopsy. A post-transplant skin biopsy can provide patient-derived constitutional material after the fibroblasts are cultured. The approach adds a minor procedure and commonly requires several weeks of culture time, often around four to eight weeks.

3. Hair bulb or other nonhematopoietic samples. Hair bulbs may sometimes be used, but DNA quantity and quality can be limiting, and the suitability of the sample depends on the laboratory’s assay and the variant being sought.

The question is not simply whether a sample can produce DNA. It is whether the DNA represents the child’s germline material and is adequate for the test being requested. A laboratory should be consulted before collection, because the preferred specimen can differ according to the suspected variant type and the testing platform.

If a child received a transplant for a presumed IEI that was never genetically confirmed, retrospective testing may require archived material or a punch biopsy. Workups can stall for months when the transplant team did not bank DNA and the family assumes that a fresh blood or saliva sample will be sufficient. The sampling plan belongs in the transplant conversation before the procedure, not as an afterthought once a diagnosis is needed for the child or the family.

This also matters for relatives. Once a familial variant is identified, testing parents and siblings may be relatively straightforward, but the affected child’s post-transplant sample still has to be valid. A contaminated or donor-derived specimen can lead to an incorrect conclusion about inheritance and complicate counseling for future pregnancies.

Putting the workflow together

The preparation process is easier to manage when the clinical team treats it as a sequence rather than as a single laboratory order.

First, define the phenotype in enough detail to guide the test. “Recurrent infections” is a starting point, not a final description. The record should distinguish respiratory infections from invasive bacterial disease, viral complications, fungal infections, persistent diarrhea, inflammatory disease, and treatment-related complications. Age at onset and response to treatment often provide as much direction as the number of infections.

Next, complete the three-generation pedigree and gather available records. The aim is not to create a perfect family archive. It is to identify inheritance clues, early deaths, similarly affected relatives, consanguinity, and diagnoses that may alter the test strategy.

Then review the functional immune evaluation. Genetic testing is more informative when the laboratory receives a clear clinical indication and the ordering team already knows which immune compartments appear abnormal. It also prevents the common mistake of using sequencing as a substitute for basic immune characterization.

After that, choose the modality. A targeted panel may be appropriate for a recognizable IEI phenotype, while WES or WGS may be preferable for a multisystem presentation, a negative panel, or a suspected disorder outside the conventional IEI gene list. Trio testing should be considered at this stage, not after an ambiguous result has already returned.

Before the sample is collected, check whether the child has undergone transplantation or is receiving treatment that could affect the specimen. For post-transplant patients, a blood sample may not provide constitutional DNA, and saliva may be contaminated. The laboratory needs to approve the sampling strategy in advance.

Finally, address immediate safety and financial issues in parallel. Live-attenuated vaccines should remain on hold when severe T-cell or combined immunodeficiency is suspected until an immunologist clears them. Insurance authorization, expected patient responsibility, assistance programs, and the possibility of reanalysis should be discussed before the family receives an unexpected bill.

Verdict

Preparing for genetic testing for a suspected inborn error of immunity is not a single appointment. It is a sequenced workflow with several non-negotiable inputs.

The three-generation family history sharpens both test selection and variant interpretation. The choice between a targeted panel and broad sequencing should reflect the phenotype, prior functional workup, and the cost the family can realistically manage. The stated financial ranges are straightforward: approximately $1,500 for a targeted panel when not covered, compared with approximately $4,000–$12,000 for WES or WGS. The difference is real, but it is not a fixed six- to eight-fold rule.

Live-attenuated vaccine precautions cannot wait for genetic results. The vaccine hold has to be communicated to every clinician involved in the child’s care, because a negative panel does not exclude an immune defect and does not provide vaccine clearance. For children who have undergone transplantation, the specimen itself becomes part of the diagnostic problem: donor-derived blood and contaminated saliva can obscure the child’s constitutional genetics.

The limits of testing are not a reason to avoid it. They are a reason to prepare properly. A negative panel does not exclude an IEI, sequencing can miss certain variant types and newly recognized genes, and functional immunological assays provide information that genetics cannot replace. The preparation work is what turns a laboratory result into a clinical answer.